gastric or gastroesophageal junction cancer
Conditions
Interventions
None listed
Sponsors
St.Marianna University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age 20 years or older at the time of obtaining consent. (2) Patients must have gastric cancer or gastroesophageal junction cancer pathologically diagnosed as adenocarcinoma. (3) The patient has been diagnosed as Stage II or Stage III (Cancer Treatment Code, 15th Edition) and has received adjuvant chemotherapy after radical resection. (4) The patient has been diagnosed with gastric cancer recurrence by imaging examination and is scheduled to receive anticancer drug therapy for the recurrent lesion. (5) Tumor tissue from the primary tumor site is available for gene panel testing. (6) Written consent has been obtained.
Exclusion criteria
Exclusion criteria: (1) Has other malignancy (excluding intraepithelial cancer) within 2 years. (2) The patient is not expected to survive for more than 12 weeks. (3) The principal investigator judges that participation in this study is inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The detection rate of therapeutic target genetic alterations in ctDNA | — |
Secondary
| Measure | Time frame |
|---|---|
| The genetic profiles detected by ctDNA The genetic profile obtained by gene panel test using primary tumor tissue. Time from resection of the primary tumor to detection of recurrence. Progression-free survival and response rate for each treatment. Overall survival from the initiation of first-line chemotherapy. | — |
Countries
Japan
Contacts
Public ContactHiroyuki Takeda
St.Marianna University School of Medicine Clinical Oncology
Outcome results
None listed